KRAS

Asia

Pharma

Roche, Asahi Kasei, Verastem—Fierce Pharma Asia

Roche inked a $1.2 billion obesity deal with China's Rona. Asahi Kasei won a first-in-class FDA nod. Verastem's KRAS drug showed strong early data.

Angus Liu Oct 16, 2026 7:57am

paper paperclips

FDA’s Rasonque review documents pressure RevMed

Oct 9, 2026 11:25am

launch

As RevMed preps for ‘historic’ cancer launch, questions linger

Aug 27, 2026 11:27am

Revolution Medicines booth at ASCO 2026

FDA greenlights RevMed’s pancreatic cancer gamechanger

Aug 26, 2026 11:30am

arrow miss target fail attempt try

BMS details Krazati confirmatory fail in colorectal cancer

Jul 7, 2026 10:46am

Revolution Medicines booth at ASCO 2026

Fierce Biotech

ASCO: RevMed confident in RAS leadership as rivals square up

May 31, 2026 8:00am